EUVIMEDEUVIMED entdecken
Open Access

Outcomes and Toxicity of Adult Medulloblastoma Treated with Pediatric Multimodal Protocols: A Single-Institution Experience

Antonio Ruggiero, Dario Talloa, Alberto Romano, Giorgio Attinà, Stefano Mastrangelo, Palma Maurizi, Tommaso Verdolotti, Gianpiero Tamburrini, Silvia Chiesa, Rina di Bonaventura, Pier Paolo Mattogno, Alessandro Olivi und 1 weitere

Oncology Research · 2025 · 33 (12) · 3855-3867

DOI: 10.32604/or.2025.067948 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2025. Verfasst von Antonio Ruggiero und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, 00168, Italy. Hauptthemen laut MEDLINE: Medulloblastoma, Cerebellar Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adult medulloblastoma (MB) represents less than 1% of central nervous system malignancies, lacking standardized therapeutic approaches due to its rarity. This retrospective single-center analysis aimed to assess survival outcomes and treatment-associated toxicities in adult MB patients managed with pediatric-derived protocols.

Methods

Eighteen patients (≥18 years) with MB treated at Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) (January 1997-January 2024) were analyzed. All received craniospinal radiotherapy with posterior fossa boost, followed by adjuvant chemotherapy utilizing pediatric regimens (PNET3, PNET4, PNET5, or high-risk protocols incorporating high-dose chemotherapy with autologous stem cell rescue). Primary outcomes included overall survival (OS) and progression-free survival (PFS). Secondary analyses focused on comprehensive toxicity assessment.

Results

The cohort included 11 males and 7 females (median age: 23 years). Metastatic disease was present in 6 patients (33%) at diagnosis. Histopathological distribution showed classic MB (55.5%), desmoplastic/nodular (39%), and large cell/anaplastic variants (5.5%). Molecular subgrouping (available in 6 patients) identified SHH subgroup in four cases and WNT subgroup in two. Three-year and five-year overall survival rates reached 94.5% and 88.8%, respectively. Treatment-related adverse events included grade 3-4 hematologic toxicities, clinically significant weight loss, and grade ≥3 neurological and ototoxic complications. These toxicities necessitated treatment modifications including dose adjustments, cycle delays, and occasional early discontinuation.

Conclusions

Adult MB patients treated with pediatric-adapted protocols demonstrated excellent long-term survival outcomes, comparable to or surpassing historical data. Despite frequent toxicity requiring treatment modifications, these regimens proved feasible with acceptable risk-benefit profiles. These results support implementing modified pediatric protocols for adult MB management. Future multicenter investigations with larger cohorts are essential for refining risk stratification, optimizing treatment intensity, and evaluating long-term outcomes in this rare malignancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedulloblastomaCerebellar NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAdultRetrospective StudiesYoung AdultAdolescentCombined Modality TherapyTreatment OutcomeMiddle Aged

Stichwörter der Autor:innen

Medulloblastomaadultchemotherapychildrentoxicity

Autor:innen und Institutionen

  • Pediatric Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, 00168, Italy.
  • Department of Women and Child Health and Public Health, Università Cattolica del Sacro Cuore, Rome, 00168, Italy.
  • ARC Advanced Radiology Center (ARC), Department of Oncological Radiotherapy and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, 00168, Italy.
  • Pediatric Neurosurgery, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, 00168, Italy.
  • Department of Neuroscience, Section of Neurosurgery, Università Cattolica del Sacro Cuore, Rome, 00168, Italy.
  • Gemelli Advanced Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, 00168, Italy.

Zitieren

APA

Ruggiero, A., Talloa, D., Romano, A., Attinà, G., Mastrangelo, S., Maurizi, P., Verdolotti, T., Tamburrini, G., Chiesa, S., di Bonaventura, R., Mattogno, P. P., Olivi, A., & Albanese, A. (2025). Outcomes and Toxicity of Adult Medulloblastoma Treated with Pediatric Multimodal Protocols: A Single-Institution Experience. Oncology Research, 33(12), 3855-3867. https://doi.org/10.32604/or.2025.067948

Vancouver

Ruggiero A, Talloa D, Romano A, Attinà G, Mastrangelo S, Maurizi P, et al. Outcomes and Toxicity of Adult Medulloblastoma Treated with Pediatric Multimodal Protocols: A Single-Institution Experience. Oncology Research. 2025;33(12):3855-3867. doi:10.32604/or.2025.067948

BibTeX
@article{Ruggiero2025,
  author = {Ruggiero, Antonio and Talloa, Dario and Romano, Alberto and Attinà, Giorgio and Mastrangelo, Stefano and Maurizi, Palma and Verdolotti, Tommaso and Tamburrini, Gianpiero and Chiesa, Silvia and di Bonaventura, Rina and Mattogno, Pier Paolo and Olivi, Alessandro and Albanese, Alessio},
  title = {Outcomes and Toxicity of Adult Medulloblastoma Treated with Pediatric Multimodal Protocols: A Single-Institution Experience},
  journal = {Oncology Research},
  year = {2025},
  volume = {33},
  number = {12},
  pages = {3855--3867},
  doi = {10.32604/or.2025.067948}
}
Kostenlos starten →